INTRODUCTION
============

Glioblastomas (glioblastoma multiforme \[GBM\]) are the most common and aggressive malignant brain tumor, with a median survival from diagnosis of approximately 12 to 14 months.^[@R1]^ The majority of glioblastomas (∼90%) occur without evidence of a less malignant precursor lesion (primary glioblastomas) in older patients, whereas secondary glioblastomas progress from low-grade diffuse astrocytoma or anaplastic astrocytoma, and occur in younger patients.^[@R2]^ Secondary glioblastomas have a significantly better prognosis than primary glioblastoma.^[@R2]^

Approximately 70% to 80% of secondary glioblastomas have somatic mutation in the isocitrate dehydrogenase 1 (*IDH1*) gene, which are absent in primary glioblastoma.^[@R3]--[@R5]^ Wild-type IDH1 protein is found in the cytoplasm, peroxisomes, and endoplasmic reticulum, and catalyzes the oxidative decarboxylation of isocitrate to α-ketogluterate.^[@R6]--[@R8]^ Mutations in *IDH1* associated with glioblastomas map to the highly conserved residue R132 in the enzyme active site, and usually result in an Arg to His substitution, although other substitutions can also occur.^[@R8]--[@R12]^ The *IDH1 R132* mutation occurs in 55% to 80% of grade II and III oligodendrogliomas and astrocytomas, but is rare in primary glioblastomas.^[@R12]^ To a lesser extent, glial tumors have somatic mutations in the corresponding codon (codon R172) of the *IDH2* gene.^[@R9]^ The IDH2 protein has a similar function to IDH1, but is found in the mitochondria. Both the *IDH1-R132* and *IDH2-R172* mutations are thought to result in an accumulation of the oncometabolite 2-hydroxyglutarate instead of α-ketogluterate.^[@R13],[@R14]^

It is unclear how a tumor\'s biology is affected by *IDH1/2* mutations. *IDH1/2* mutations may result in genome-wide epigenetic changes in human gliomas.^[@R4]^ Another hypothesis is that the mutations reduce the capacity of cells to produce NADPH, and consequently lowers the ability of the cell to scavenge oxygen species, making the tumor cells more susceptible to irradiation and chemotherapy. This increased sensitivity to treatments may result in increased patient survival.^[@R15]^

A number of studies have found that *IDH1-R132* and *IDH2-R172* mutations are linked to the genomic profile of the tumor, and are important prognostic markers in grade II to IV gliomas.^[@R16]--[@R20]^ However, other studies have not found an association of *IDH1/2* mutations with prognosis in low-grade tumors.^[@R18],[@R21]^ Therefore, the prognostic value of these genetic markers for survival is not clear.

The purpose of the current study was to perform a meta-analysis to examine the association of *IDH1/2* mutations with overall survival (OS) and progression-free survival (PFS) in patients with glioblastomas.

METHODS
=======

Literature Search Strategy
--------------------------

This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines.^[@R22]^ Medline, Cochrane, EMBASE, and Google Scholar were searched from inception to January 28, 2015, using combinations of the following keywords: IDH mutation, brain tumor, glioma, glioblastoma, oligodendroglioma, prognosis. Reference lists of relevant studies were hand-searched. Meta-analyses do not involve humans and do not require Institutional Review Board approval.^[@R23]^

Study Selection and Data Extraction
-----------------------------------

Inclusion criteria were as follows: randomized controlled trials (RCTs) and prospective and retrospective studies; patients with a malignant brain tumor (glioma, glioblastoma, anaplastic oligodendroglioma, etc); provided IDH mutation data; and contained survival analysis data. Letters, comments, editorials, case reports, proceedings, and personal communications were excluded, as were studies in which no survival analysis was performed. Studies were identified by the search strategy by 2 independent reviewers. When there was uncertainty regarding eligibility, a third reviewer was consulted.

The following information/data were extracted from studies that met the inclusion criteria: the name of the first author, year of publication, study design, number of participants in each group, participants' age and sex, diagnostic criteria, tumor type and World Health Organization (WHO) grade, treatments, and survival data.

Quality Assessment
------------------

The quality of the included studies was assessed using the modified 18-items Delphi checklist, which is designed for assessing the quality of single-arm clinical studies.^[@R24]^ The quality assessment was also performed by 2 independent reviewers, and a third reviewer was consulted for any uncertainties.

Outcome Measures and Data Analysis
----------------------------------

Overall survival and PFS were used to evaluate the association of *IDH1* and *IDH1/2* mutations, and prognosis for patients with malignant brain tumors. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for OS and PFS were calculated and compared between patients with and without mutations. Pooled HRs and 95% CIs were calculated for all studies combined, and for given subgroups (e.g., *IDH* mutation type or surgery vs no surgery). A HR value \<1 indicates that mutations may prolong OS or PFS, whereas a HR value \>1 indicates the absence of mutations may decrease OS or PFS. A HR value equal to 1 indicates there was no significant association of *IDH1* or *IDH1/2* mutations with OS or PFS.

Heterogeneity among the studies was evaluated by the Cochran Q and the I^2^ statistic. A Q statistic, with a *P* \< 0.10, was considered to indicate statistically significant heterogeneity. The I^2^ statistic indicates the percentage of the observed between-study variability due to heterogeneity rather than chance, and a value \>50% was considered to indicate significant heterogeneity. Random-effects models (DerSimonian--Laird method) were used if heterogeneity was detected (I^2^ \> 50% or Q statistics *P* \< 0.1). Otherwise, fixed-effects models (Mantel--Haenszel method) were utilized. Sensitivity analysis was performed using the leave-one-out approach. Publication bias was assessed by constructing funnel plots and by Egger test. The absence of publication bias was indicated by the data points forming a symmetric funnel-shaped distribution, and a 1-tailed significance level of *P* \> 0.05 (Egger test). All statistical assessments were 2-sided, and a value of *P* \< 0.05 was considered as statistically significant. Statistical analyses were performed using the statistical software Comprehensive Meta-Analysis, version 2.0 (Biostat, Englewood, NJ).

RESULTS
=======

Search Results and Study Characteristics
----------------------------------------

A flow diagram of study selection is shown in Figure [1](#F1){ref-type="fig"}. A total of 165 studies were identified in the database search. After a review of the abstracts, 136 studies were excluded because they did not match the topic of the current analysis. Thus, 29 full-text articles were assessed for eligibility, and of these, 5 were excluded as they did not provide a quantitative outcome. Therefore, 24 studies were included in the qualitative synthesis.^[@R3],[@R13],[@R16]--[@R18],[@R21],[@R25]--[@R42]^ The characteristics and populations of the included studies are summarized in Table [1](#T1){ref-type="table"} , and OS and PFS data are summarized in Table [2](#T2){ref-type="table"}. Studies that reported median OS or PFS time were not considered for the analysis because most of the included studies were presented as HR. The study by Mukasa et al^[@R21]^ was not included in the analysis because the HRs were reported by tumor stage.

![Flow diagram of study selection.](medi-95-e2583-g001){#F1}
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Study Characteristics
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###### 

Overall Survival and Progression-free Survival in Patients With and Without *IDH1/IDH2* Mutations
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### Association of IDH1 or IDH2 Mutations With OS

A total of 15 studies with completed data of OS were included in the analysis.^[@R3],[@R13],[@R16],[@R18],[@R25]--[@R29],[@R32]--[@R34],[@R36],[@R37],[@R42]^ Significant heterogeneity was noted (I^2^ = 59.23%, Q statistic = 34.336, *P* = 0.002); therefore a random-effects model was used. The pooled HR of 0.358 (95% CI 0.264--0.487, *P* \< 0.001) indicated that *IDH1* or *IDH1/2* mutations were associated with better OS (Figure [2](#F2){ref-type="fig"}). When patients were stratified by surgery versus no surgery or *IDH1* versus *IDH1/2* mutations, the results also indicated that the presence of *IDH* mutations was associated with better OS.

![Meta-analysis for the association of IDH1/IDH2 mutations versus overall survival (OS). 1st AU = first author, 95% CI = 95% confidence interval, HR = hazard ratio, IDH = isocitrate dehydrogenase, lower limit, upper limit of HR.](medi-95-e2583-g005){#F2}

### Association of IDH1 or IDH2 Mutations With PFS

A total of 10 studies with completed data of PFS were included in the analysis.^[@R13],[@R16],[@R25]--[@R29],[@R32],[@R36],[@R37]^ Significant heterogeneity was noted (I^2^ = 53.53%, Q statistic = 19.369, *P* = 0.022); therefore a random-effects model was used. The pooled HR of 0.322 (95% CI 0.242--0.455, *P* \< 0.001) indicated that *IDH1* or *IDH1/2* mutations were associated with better PFS (Figure [3](#F3){ref-type="fig"}). When patients were stratified by surgery versus no surgery or *IDH1* versus *IDH1/2* mutations, the results also indicated that the presence of *IDH* mutations was associated with better PFS.

![Meta-analysis for the association of IDH1/IDH2 mutations versus progression-free survival (PFS). 1st AU = first author, 95% CI = 95% confidence interval, HR = hazard ratio, lower limit, upper limit of HR.](medi-95-e2583-g006){#F3}

### Sensitivity Analysis

Results of the sensitivity analysis using the leave-one-out approach for OS and PFS are shown in Figure [4](#F4){ref-type="fig"}. For both OS and PFS, the pooled estimates with each of the studies removed in turn remained statistically significant, indicating that the meta-analysis had good reliability for both measures (HRs for OS: range 0.33--0.38, all *P* values \<0.001; HRs for PFS, range 0.31--0.37, all *P* values \<0.001).

![Sensitivity analysis using the leave-one-out approach for (A) overall survival (OS) and (B) progression-free survival (PFS). 1st AU = first author, 95% CI = 95% confidence interval, HR = hazard ratio, IDH = isocitrate dehydrogenase, lower limit, upper limit of HR.](medi-95-e2583-g007){#F4}

### Publication Bias Analysis

Results of the evaluation of publication bias for OS and PFS are shown in Figure [5](#F5){ref-type="fig"}. For both measures, the funnel plots were symmetric (both *P* \< 0.001; classic fail-safe test). However, Egger test indicated that the intercepts of the funnel plots did not obtain statistical significance (OS: 1-tailed, *P* = 0.037; PFS: 1-tailed, *P* = 0.075, respectively). Hence, publication bias may exist with respect to OS.

![Evaluation of publication bias by funnel plot and the Egger test for (A) overall survival (OS) and (B) progression-free survival (PFS).](medi-95-e2583-g008){#F5}

### Quality Assessment

Results of the quality assessment using the modified 18-item Delphi checklist are shown in Table [3](#T3){ref-type="table"}. All of the included studies clearly stated the aim of the study in the abstract or introduction, and described the characteristics of the included participants. The eligibility criteria of all the studies were explicit and appropriate, and outcome measures were all well-defined. The final total Delphi checklist scores of the studies ranged from 9 to 15 (maximum possible score of 18). Overall, the results indicate the studies are of good quality.

###### 

Quality Assessment Results
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DISCUSSION
==========

The purpose of this meta-analysis was to evaluate the prognostic value of *IDH1/2* mutations with respect to OS and PFS in patients with glioblastoma. The results showed that the presence of *IDH1/2* mutations was associated with longer OS and PFS, and this result was seen in both patients treated with surgery and those treated nonsurgically (e.g., radiotherapy), as well as in patients with *IDH1* and *IDH1/2* mutations.

*IDH1* mutations have been reported in secondary GBM, diffuse astrocytoma, oligodendrogliomas, anaplastic astrocytomas, anaplastic oligodendrogliomas, and anaplastic oligoastrocytomas, and rarely in primary GBM, and have not been reported in pilocytic astrocytomas, ependymonmas, and medulloblastomas.^[@R43]^ Mutations have also been reported in other cancers including acute myeloid leukemia and colorectal and prostate cancer.^[@R43]^

Prior studies have found that *IDH1/2* mutations may influence the prognosis of patients with secondary or greater than grade II gliomas; however, these studies have differed in design and the results have not always been consistent.^[@R16]--[@R21],[@R44]^

Evidence has generally shown that *IDH1* mutations are associated with improved OS and PFS, particularly in patients with high-grade gliomas.^[@R9],[@R13],[@R27]^ The prognostic value in low-grade gliomas is, however, less clear. For example, Sanson et al^[@R19]^ showed that the *IDH1* mutation had a significant prognostic value for OS in gliomas, whereas Kim et al^[@R18]^ reported the *IDH1/IDH2* mutation was of no prognostic value in 360 low-grade gliomas. Interestingly, although *IDH1* mutations have generally been shown to be a prognostic indicator, their presence is not necessarily predictive of response to therapy.^[@R9],[@R13],[@R19],[@R40]^ Reasons for these findings may have to do with the association of *IDH1* mutations with O^6^-methylguanine-DNA methyltransferase (MGMT) promoter methylation status.^[@R42]^ For example, Molenaar et al^[@R45]^ reported that the combination of *IDH1* mutations and MGMT methylation status predicted survival in patients with glioblastomas better than either *IDH1* or MGMT status alone. Though the reasons for the associations between survival, and *IDH1* and MGMT methylation status remain to be determined, it has been suggested there may be mechanistic link between *IDH1* mutations and MGMT methylation.^[@R46]^

Prior studies have suggested that chemoradiotherapy may be effective for a subset of patients with gliomas, as the addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy conferred a significant increase in OS and PFS.^[@R47],[@R48]^ Among the studies included in the current analysis, Okita et al^[@R28]^ suggested *IDH1/2* mutations were predictive for response to chemoradiotherapy, but not radiotherapy alone in patients with grade II gliomas. However, van den Bent et al^[@R13]^ reported that *IDH1* mutations were predictive of both OS and PFS for patients treated with radiotherapy and radiotherapy/PVC. It has also been reported that patients with low-grade gliomas were sensitive to temozolomide.^[@R17]^ In the current meta-analysis, we did not evaluate the predictive value of *IDH1/2* mutations with respect to radiotherapy, chemotherapy, or chemoradiotherapy. This was due to the heterogeneity across the studies, and because few studies directly evaluated this question.

Other prior meta-analyses have evaluated the association of *IDH* mutations and survival in patients with glioblastomas. An analysis by Cheng et al^[@R49]^ included 9 studies with a total of 1669 patients with glioblastomas, and, similar to our results, found that *IDH1* mutations were associated with improved OS. Zou et al^[@R50]^ performed a meta-analysis including 12 studies with a total of 2190 patients, and reported HRs for OS and PFS in patients with *IDH* mutations were 0.33 (95% CI 0.25--0.42) and 0.38 (95% CI 0.21--0.68), respectively, as compared with glioma patients with the wild-type *IDH* gene. Subgroup analyses based on tumor grade also showed that the presence of *IDH* mutations was associated with better outcomes.

There are several limitations to this analysis that should be considered when interpreting the results. We did not evaluate whether the histological subtype or tumor grade influenced the association of *IDH1/2* mutations with the survival outcomes of patients with secondary GBM. As mentioned above, we also did not evaluate whether the type of treatment regimen influenced the prognostic value of *IDH1/2* mutations of patients with secondary GBM. Furthermore, significant heterogeneity was present among the studies for both OS and PFS with respect to tumor type and grade, treatments, method for calculating endpoints, and method for determining the presence of mutations. Publication bias may be present as well, for those studies without significance might not be submitted or published.

CONCLUSIONS
===========

In summary, the results of this meta-analysis indicate that *IDH1/2* mutations are associated with improved survival in patients with glioblastomas.

Abbreviations: CI = confidence interval, GBM = glioblastoma multiforme, HR = hazard ratio, IDH = isocitrate dehydrogenase 1, OS = overall survival, PCV = procarbazine, lomustine, and vincristine, PFS = progression-free survival, RCT = randomized controlled trial, WHO = World Health Organization.

The authors have no conflicts of interest to disclose.
